Evidence map›Paper›PMID 35681566›Full record

ArticleCancers2022

Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma.

Takahiro Kodama, Michiko Kodama, Nancy A Jenkins, Neal G Copeland, Huanhuan Joyce Chen, Zhubo Wei

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Takahiro KodamaHouston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA.ORCID 0000-0002-6250-1324
Michiko KodamaHouston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA.ORCID 0000-0003-4046-7572
Nancy A JenkinsHouston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA.
Neal G CopelandHouston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA.
Huanhuan Joyce ChenThe Pritzker School of Molecular Engineering, The University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-1446-7184
Zhubo WeiHouston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA.
Houston Methodist · USUniversity of Chicago · US

Funding

Cancer Prevention Research Institute of Texas pendingJapan Agency for Medical Research and Development JP22fk0210074 JP22fk0210091 JP22fk0210110 JP22fk0310524
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide and the only cancer with an increasing incidence in the United States. Recent advances in sequencing technology have enabled detailed profiling of liver cancer genomes and revealed extensive inter- and intra-tumor heterogeneity, making it difficult to identify driver genes for HCC. To identify HCC driver genes, we performed transposon mutagenesis screens in a mouse HBV model of HCC and discovered many candidate cancer genes (SB/HBV-CCGs). Here, we show that one of these genes, RNF125 is a potent anti-proliferative tumor suppressor gene in HCC. RNF125 is one of nine CCGs whose expression was >3-fold downregulated in human HCC. Depletion of RNF125 in immortalized mouse liver cells led to tumor formation in transplanted mice and accelerated growth of human liver cancer cell lines, while its overexpression inhibited their growth, demonstrating the tumor-suppressive function of RNF125 in mouse and human liver. Whole-transcriptome analysis revealed that RNF125 transcriptionally suppresses multiple genes involved in cell proliferation and/or liver regeneration, including Egfr, Met, and Il6r. Blocking Egfr or Met pathway expression inhibited the increased cell proliferation observed in RNF125 knockdown cells. In HCC patients, low expression levels of RNF125 were correlated with poor prognosis demonstrating an important role for RNF125 in HCC. Collectively, our results identify RNF125 as a novel anti-proliferative tumor suppressor in HCC.

Indexed as

anti-proliferationdriver geneshepatocellular carcinomaRNF125tumor suppressorwhole-transcriptome analysis

Identifiers

PMID35681566
PMCPMC9179258
OpenAlexW4281489926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.